Liposome nanocarrier, preparation method thereof and application thereof in treating allergic rhinitis

Abstract

This invention discloses a liposome nanocarrier, its preparation method, and its application in the treatment of allergic rhinitis, belonging to the field of biomedical nanomaterials. The liposome nanocarrier comprises liposomes and siRNA carried by the liposomes; the preparation method includes: (1) dissolving lipids, cholesterol, distearate phosphatidylcholine, and DMG-PEG 2000 in cyclohexane to generate a thin film; hydrating the film with ammonium sulfate, dialyzing, and extruding using a liposome extruder to obtain liposomes; (2) mixing the liposomes with siRNA and vortexing to obtain the liposome nanocarrier. This invention uses liposomes as a carrier to carry siRNA, preparing a liposome nanocarrier. Experimental verification shows that this liposome nanocarrier can target and treat allergic rhinitis. This invention changes the current situation of ineffective and repetitive treatment with conventional allergic rhinitis sprays, improving the treatment effect of rhinitis.

Description

Technical Field

[0001] This invention relates to the field of biomedical nanomaterials, and in particular to a liposome nanocarrier, its preparation method, and its application in the treatment of allergic rhinitis. Background Technology

[0002] Allergic rhinitis (AR) is one of the most common allergic diseases worldwide. It is defined as a chronic inflammation of the nasopharynx, with typical symptoms including nasal congestion, runny nose, sneezing, and itching. The inflammatory cascade in AR is triggered by IgE-dependent mast cell degranulation and the release of histamine from other mediators. Mast cell histamine plays an axial role in the development of allergy-related inflammatory diseases by regulating leukocyte maturation and activation, and further coordinated and guided by TH2 cytokines IL-4, IL-5, and / or IL-13 to migrate to targets that cause chronic inflammation.

[0003] Currently, conventional treatments for allergic rhinitis include avoiding allergens, nasal irrigation with saline solution, oral antihistamines, nasal corticosteroids, combined nasal corticosteroids and antihistamines, and allergen immunotherapy. However, these medications only provide short-term relief of allergic rhinitis symptoms, and unavoidable side effects (such as nasal mucosal damage) limit their long-term clinical application. Therefore, there is an urgent need to develop novel therapeutic agents that target the pathogenesis of allergic rhinitis to improve side effects and patient compliance.

[0004] Circular RNAs (circRNAs) are novel endogenous non-coding RNAs formed by alternative splicing of precursor mRNAs with specific terminal anticomplementation, resulting in circular RNAs. CircRNAs are highly stable and relatively abundant, exhibiting specific expression patterns at cellular, tissue, and developmental stages. In recent years, evidence has emerged suggesting that circRNAs are involved in the development and progression of inflammation-related diseases. Studies of circRNA profiles in peripheral blood leukocytes of patients with type 2 diabetes mellitus (T2DM) have revealed upregulation of circRNA circANKRD36, which is positively correlated with the inflammatory cytokine IL-6. circANKRD36 may participate in T2DM and inflammation-related pathways through interactions with miRNAs. Although research on circRNAs in allergic rhinitis is limited, existing studies have found that circRNAs also play an important role in this condition.

[0005] Liposomes, the earliest type of LNPs, can transport hydrophobic or hydrophilic molecules, including small molecules, proteins, and nucleic acids. They are a versatile nanocarrier platform with higher bioavailability and selectivity than free drugs. Liposome-based nanocarriers can reduce the toxicity of anticancer drugs to normal tissues, increase the water solubility of hydrophobic drugs, prolong drug residence time, and improve control over drug release. Furthermore, liposomes were among the first nanomedicine delivery platforms to successfully translate from concept to clinical application, with many liposomal drug formulations approved and successfully used in medical practice. Notably, Patisiran (ONPATTRO), a nucleic acid drug approved by the FDA in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis, was the first approved siRNA drug and LNP formulation nucleic acid drug, marking a significant milestone in the development of nucleic acid therapy. Therefore, liposomal small nucleic acid drugs are expected to become one of the main approaches to disease treatment in the future. Summary of the Invention

[0006] The purpose of this invention is to provide a liposome nanocarrier, its preparation method, and its application in the treatment of allergic rhinitis, so as to solve the problems existing in the prior art. This liposome nanomaterial can be used to target and treat allergic rhinitis.

[0007] To achieve the above objectives, the present invention provides the following solution:

[0008] The present invention provides a liposome nanocarrier, comprising liposomes and siRNA carried by the liposomes, wherein the nucleotide sequence of the siRNA is: sense strand (SEQ ID NO:1): GAUGCCACCUGGAAUGUGGTT; antisense strand (SEQ ID NO:2): CCACAUUCCAGGUGGCAUCTT.

[0009] This invention also provides a method for preparing the aforementioned liposome nanocarrier, comprising the following steps:

[0010] (1) Preparation of liposomes

[0011] Lipids, cholesterol, distearate phosphatidylcholine, and DMG-PEG 2000 were dissolved in cyclohexane and reacted to form a film; the film was hydrated with ammonium sulfate, dialyzed, and extruded using a liposome extruder to obtain liposomes;

[0012] (2) Preparation of liposome nanocarriers

[0013] The liposomes were mixed with siRNA and vortexed to obtain liposome nanocarriers.

[0014] Preferably, in step (1), the molar ratio of the lipids, cholesterol, distearate phosphatidylcholine and DMG-PEG2000 is 50:38.5:10:1.5.

[0015] Preferably, in step (1), the conditions for generating the thin film are: rotary evaporation at 37°C for 30 min.

[0016] Preferably, in step (1), the concentration of ammonium sulfate is 250 mM and the hydration time is 1 h.

[0017] Preferably, in step (1), the lipids are prepared by the following method:

[0018] The lipids were obtained by continuous high-temperature stirring of 1,3-propanediamine and 1,2-epoxyhexane followed by gradient elution with CH2Cl2, CH3OH, and NH4OH. The gradient elution was carried out sequentially with a mixture of CH2Cl2, CH2Cl2, CH3OH, and NH4OH for 20 min. The volume ratio of CH2Cl2, CH3OH, and NH4OH in the mixture was 75:22:3.

[0019] Preferably, the molar ratio of 1,3-propanediamine to 1,2-epoxyhexane is 1:1; the high-temperature stirring conditions are: stirring at 90°C for 2.5 h.

[0020] Preferably, in step (2), the molar ratio of the liposome to the siRNA is (15-70):1.

[0021] The present invention also provides the application of the liposome nanocarrier in the preparation of a drug for treating allergic rhinitis.

[0022] The present invention also provides a drug for targeted treatment of allergic rhinitis, comprising the aforementioned liposome nanocarrier and a pharmaceutically acceptable carrier.

[0023] The present invention discloses the following technical effects:

[0024] This invention utilizes liposomes as carriers to encapsulate siRNA, thus preparing a liposome nanocarrier. The preparation method of this liposome nanocarrier is simple and the conditions are easily controlled. Experiments have shown that this liposome nanocarrier has small particle size, good monodispersity, and good stability. Compared with liposomes or siRNA alone, it can significantly promote cell activity, reduce cellular oxidative stress, and reduce cellular inflammatory responses, while exhibiting low cytotoxicity, enabling targeted treatment of allergic rhinitis. This invention addresses the shortcomings of previous allergic rhinitis nasal sprays, which were ineffective and required repeated treatments, and can significantly improve the treatment effect of rhinitis. Attached Figure Description

[0025] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0026] Figure 1 SEM characterization of Lipo@siRNA for scanning electron microscopy observation;

[0027] Figure 2 The particle size determination results for Lipo@siRN;

[0028] Figure 3 The results show the stability of Lipo in PBS.

[0029] Figure 4 The results of cell viability detection using the MTT assay;

[0030] Figure 5 To detect the levels of ROS, GSH, and MDA in cells of each group;

[0031] Figure 6 The levels of IL-6, IL-8, and TLSP in cells of each group were detected using an ELISA kit.

[0032] Figure 7 The expression level of IL-6 in cells of each group was detected by qPCR.

[0033] Figure 8 The expression level of IL-8 in cells of each group was detected by qPCR.

[0034] Figure 9 The expression level of TLSP in cells of each group was detected by qPCR.

[0035] Figure 10 The expression level of TLR4 in cells of each group was detected by qPCR.

[0036] Figure 11 The expression level of Homo-circ_0008668 in cells of each group was detected by qPCR.

[0037] Figure 12 The expression level of has-miR-6089 in cells of each group was detected by qPCR.

[0038] Figure 13 This is the result of flow cytometry analysis. Detailed Implementation

[0039] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0040] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0041] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0042] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This application specification and embodiments are merely exemplary.

[0043] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0044] Example 1: Preparation, characterization and identification of liposome nanocarrier Lipo@siRNA

[0045] 1. Preparation method of liposome nanocarrier Lipo@siRNA

[0046] (1) Lipid synthesis

[0047] 1,3-Propanediamine and 1,2-epoxyhexane (1 mmol) were added to a 2 mL glass vial in a molar ratio of 1:1, and the mixture was stirred continuously at 90 °C for 2.5 days. The lipids were then eluted sequentially using a gradient elution with CH2Cl2 and CH2Cl2 / CH3OH / NH4OH (volume ratio 75:22:3). The resulting lipids were stored at 2–8 °C.

[0048] (2) Preparation of liposomes Lipo

[0049] Lipids, cholesterol, distearate phosphatidylcholine (DSPC), and DMG-PEG 2000 were dissolved in cyclohexane at a specific ratio (molar ratio 50:38.5:10:1.5), and the solution was rotary evaporated at 37°C for 30 min. The resulting film was hydrated with 30 mL of 250 mM (NH4)2SO4 for 1 h, and then dialyzed in PBS for 3 h. Finally, the product was extruded sequentially using liposome extruders with 200 nm, 100 nm, and 50 nm membranes, and the resulting products were stored at 2–8°C.

[0050] (3) Preparation of Lipo@siRNA

[0051] Take a certain amount of the above Lipo solution and add it to 5 mL of citrate-sodium citrate buffer (pH=3, 100mM). Then add siRNA (Lipo and siRNA in different molar ratios) and vortex rapidly. Wash with citrate-sodium citrate buffer by centrifugation to remove any uncaptured siRNA.

[0052] 2. Characterization of Lipo@siRNA liposome nanocarrier

[0053] (1) SEM characterization

[0054] The sample was dropped onto a silicon wafer, dried, and then observed at a working voltage of 3kV. The results are as follows: Figure 1 As shown, scanning electron microscopy reveals that Lipo@siRNA nanoparticles are spherical and exhibit good monodispersity.

[0055] (2) Particle size determination

[0056] like Figure 2 As shown, the nanoliposomes loaded with siRNA have a particle size of approximately 127.31 nm and a PDI index of 0.09, indicating that the nanocarrier system has good monodispersity.

[0057] (3) Determination of the stability of Lipo in PBS

[0058] like Figure 3 As shown, after being placed in PBS buffer for 90 days, the particle size did not change significantly, indicating that the extruded liposomes have good stability.

[0059] (4) Loading efficiency of siRNA after different molar ratios of liposomes and siRNA.

[0060] The loading rate of liposomes was measured using a Nanodrop spectrophotometer. The results are shown in Table 1 below. The loading rate of siRNA varied with different molar ratios of liposomes to siRNA. Compared with 70:1 and 40:1, the siRNA loading rate was the highest at a molar ratio of 15:1, reaching 89.8%.

[0061] Table 1. siRNA loading efficiency

[0062]

[0063] Example 2: Cellular Experiment to Detect the Function of Lipo@siRNA

[0064] 1. Experimental Grouping

[0065] HnEpc cells in the logarithmic growth phase and in good growth condition were selected and subjected to 5 × 10⁻⁶ cells. 3 Cells / well were seeded into 96-well plates and incubated overnight at 37°C in a 5% CO2 incubator; (100 μl of sterile PBS was added to the wells around the cells as a blank control).

[0066] The cells were treated according to the following grouping:

[0067] (1) Normal group;

[0068] (2) PBS (100 μL);

[0069] (3) Lipopolysaccharide (LPS) (1 μg / ml);

[0070] (4) Lipo (1.5 μL diluted to 100 μL);

[0071] (5) si-circ RNA (4.15 nM, 100 μL);

[0072] (6) Lipo@siRNA (1.5 μL diluted to 100 μL).

[0073] Incubation time: 24 h in a 37℃, 5% CO2 incubator.

[0074] 2. MTT assay for cell viability

[0075] After the required cell culture time, add 10 μL MTT to each well and incubate at 37℃ for 4 h; aspirate the culture medium, add 150 μL DMSO and shake for 10 min; use a microplate reader to check the OD value. 568 Measure the absorbance of each well.

[0076] MTT results are as follows Figure 4As shown, compared with the control group, LPS induction significantly reduced cell activity. Compared with the Lipo group, both the si-circRNA group and the Lipo@siRNA group showed varying degrees of increased cell activity. This indicates that siRNA can effectively promote the cell activity of LPS-induced HnEpc cells, and the promoting effect is even better when applied with a vector (Lipo@siRNA).

[0077] 3. Measure ROS, GSH and MDA levels.

[0078] The reactive oxygen species (ROS) assay kit (E004, Nanjing Jiancheng Biotechnology Institute) was used to detect ROS levels in each group of cells. The reduced glutathione (GSH) assay kit (A006-2, Nanjing Jiancheng Biotechnology Institute) was used to detect GSH levels in each group of cells. The malondialdehyde (MDA) assay kit (A003-1, Nanjing Jiancheng Biotechnology Institute) was used to detect MDA content in each group of cells.

[0079] The levels of ROS, GSH, and MDA in cells of each group are as follows: Figure 5 As shown, compared with the control group, LPS-induced cells exhibited significantly increased ROS and MDA levels and significantly decreased GSH levels. Compared with the Lipo group, the siRNA and Lipo@siRNA groups showed significantly decreased ROS and MDA levels and increased GSH levels. This indicates that siRNA can significantly reduce cellular oxidative stress, and the effect is even better after loading (Lipo@siRNA).

[0080] 4. ELISA kits detect the levels of IL-6, IL-8, and TLSP.

[0081] The levels of IL-6, IL-8 and TSLP in cells of each group were detected using the IL-6 kit (E-EL-H6156 elabscience), the IL-8 kit (E-EL-H6008 elabscience), and the TSLP kit (E-EL-H1598 celabscience).

[0082] The levels of IL-6, IL-8 and TLSP in each group are as follows: Figure 6 As shown, LPS-induced cellular IL-6, IL-8, and TLSP levels were significantly increased, while siRNA significantly reduced these levels. Furthermore, the reduction effect on IL-6, IL-8, and TLSP was even stronger after Lipo@siRNA was introduced. Therefore, Lipo@siRNA can reduce the levels of inflammatory factors in cells, thereby reducing cellular inflammatory responses.

[0083] 5. qPCR detection of expression levels of IL-6, IL-8, TLSP, TLR4, circRNA, and miR6089

[0084] The qPCR detection steps for IL-6, IL-8, TLSP, TLR4, circRNA, and miR6089 are as follows:

[0085] 5.1 PCR Amplification

[0086] 5.1.1 RNA extraction using the Trizol method

[0087] 1) Add 1 mL of Trizol reagent, mix well by pipetting, transfer to a 1.5 mL EP tube without RNase, and lyse for 10 min.

[0088] 2) Add 200 μL of chloroform, mix vigorously by inverting several times, and let stand at room temperature for 5 minutes.

[0089] 3) Centrifuge at 4℃, 12000 rpm for 15 min. You can see that it separates into three phases: upper (RNA), middle (protein), and lower (DNA).

[0090] 4) Transfer the upper aqueous phase (approximately 400 μL) to another new 1.5 mL EP tube, add 400 μL of isopropanol, mix well, and let stand at room temperature for 10 min.

[0091] 5) Centrifuge at 4℃, 12000 rpm for 10 min. A white RNA precipitate will be visible at the bottom of the tube.

[0092] 6) Discard the supernatant, add 1 ml of RNase-free 75% ethanol, vortex to mix, and centrifuge at 4°C, 10000 rpm for 5 min.

[0093] 7) Repeat step 6 once.

[0094] 8) Discard the supernatant, air-dry the RNA precipitate for 5-10 min, and dissolve the precipitate in 20 μL of DEPC water.

[0095] 9) Take 2 μL of the dissolved RNA and measure the OD using a micro spectrophotometer. 260 OD 280 and OD 260 / OD 280 The values ​​are used to calculate the purity and concentration of RNA.

[0096] According to OD 260 / OD 280 The ratio is used to estimate RNA quality; a ratio between 1.8 and 2.0 meets experimental requirements. The concentration of RNA in the sample is calculated based on the absorbance value using the following formula:

[0097] Total RNA concentration (μg / μL) = OD 260 ×40×10-3

[0098] Total RNA was stored at -80°C for later use.

[0099] 5.1.2 RT reverse transcription into cDNA

[0100] Reverse transcription reaction system: (two-step method)

[0101] RT1: Genomic DNA removal. Mix the reactants according to the reaction system in Table 2 and incubate at 42°C for 2 min.

[0102] Table 2 Reverse transcription reaction system-1

[0103]

[0104] RT2: Prepare the reverse transcription reaction system - 2,

[0105] Table 3 Reverse transcription reaction system-2

[0106]

[0107] Reaction conditions: 50℃ for 15 min; 85℃ for 5 s; 4℃ for 10 min.

[0108] 5.2 Real-time quantitative PCR detection

[0109] The reaction system is shown in Table 4:

[0110] Table 4 Real-time quantitative PCR reaction system

[0111]

[0112] The reaction procedure is shown in Table 5:

[0113] Table 5 Real-time quantitative PCR reaction procedure

[0114]

[0115] The primer sequences used for gene testing are shown in Table 6 below:

[0116] Table 6 Primer sequence listing

[0117]

[0118] Universal primer for the antisense strand of microRNA: R primer: CCAGTGCAGGGTCCGAGGTATT.

[0119] qPCR test results as follows Figures 7-12As shown, compared with the control group, the expression of IL-6, IL-8, TSLP, and TLR4 genes in HnEpc cells was significantly increased after LPS induction. Compared with the LPS group, the expression of IL-6, IL-8, TSLP, and TLR4 genes in the siRNA group and Lipo@siRNA group were all decreased to varying degrees. This indicates that siRNA can effectively inhibit LPS-induced cellular inflammatory responses, and its mechanism may be related to the inhibition of the TLR4 signaling pathway and the expression of related inflammatory factors. Moreover, the inhibitory effect is stronger after application using a vector (Lipo@siRNA).

[0120] Compared with the control group, LPS-induced cells showed significantly increased expression of circRNA-0008668 and significantly decreased expression of miRNA-6089. Compared with the lipo group, the lipo@siRNA group showed significantly decreased expression of circRNA-0008668 and significantly increased expression of miRNA-6089. This indicates that siRNA can affect the expression of circRNA-0008668 and miRNA-6089, with the effect being more pronounced after loading (Lipo@siRNA).

[0121] 6. Flow cytometry detection of cell apoptosis

[0122] The steps for detecting cell apoptosis in each group are as follows:

[0123] (1) After the required time for cell treatment, trypsin digestion was performed to collect the cells, and the cells were rinsed twice with PBS and centrifuged at 1200 rpm for 5 min.

[0124] (2) Follow the instructions for use of the Annexin V-FITC / PI apoptosis detection kit:

[0125] A. Add 500 μL Binding Buffer and resuspend the cells;

[0126] B. Add 5 μL Annexin V-FITC and mix well, then add 5 μL PI and mix well;

[0127] C. React at room temperature in the dark for 5-15 minutes (with a negative control set up, i.e., normal cells without Annexin V-FITC and PI).

[0128] (3) Flow cytometer detection.

[0129] Flow cytometry results as follows Figure 13As shown, compared with the control group, the apoptosis level of cells induced by LPS was significantly increased. Compared with the Lipo group, the apoptosis level of the Lipo@siRNA group was significantly decreased. Compared with the LPS group, the apoptosis levels of the siRNA group and the Lipo@siRNA group were reduced to varying degrees, indicating that Lipo@siRNA has lower cytotoxicity.

[0130] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A liposomal nanocarrier, characterized by, The siRNA includes liposomes and siRNA carried by the liposomes, wherein the nucleotide sequence of the siRNA is: sense strand: GAUGCCACCUGGAAUGUGGTT; and antisense strand: CCACAUUCCAGGUGGCAUCTT; The preparation method of the liposome nanocarrier includes the following steps: (1) Preparation of liposomes Lipids, cholesterol, distearate phosphatidylcholine, and DMG-PEG 2000 were dissolved in cyclohexane and reacted to form a film; the film was hydrated with ammonium sulfate, dialyzed, and extruded using a liposome extruder to obtain liposomes; (2) Preparation of liposome nanocarriers The liposomes were mixed with siRNA and vortexed to obtain liposome nanocarriers; The lipids are prepared by the following method: The lipids were obtained by continuous high-temperature stirring of 1,3-propanediamine and 1,2-epoxyhexane followed by gradient elution with CH2Cl2, CH3OH, and NH4OH. The gradient elution was carried out sequentially with a mixture of CH2Cl2, CH2Cl2, CH3OH, and NH4OH for 20 min. The volume ratio of CH2Cl2, CH3OH, and NH4OH in the mixture was 75:22:

3.

2. The method for preparing liposome nanocarriers as described in claim 1, characterized in that, Includes the following steps: (1) Preparation of liposomes Lipids, cholesterol, distearate phosphatidylcholine, and DMG-PEG 2000 were dissolved in cyclohexane and reacted to form a film; the film was hydrated with ammonium sulfate, dialyzed, and extruded using a liposome extruder to obtain liposomes; (2) Preparation of liposome nanocarriers The liposomes were mixed with siRNA and vortexed to obtain liposome nanocarriers; In step (1), the lipids are prepared by the following method: The lipids were obtained by continuous high-temperature stirring of 1,3-propanediamine and 1,2-epoxyhexane followed by gradient elution with CH2Cl2, CH3OH, and NH4OH. The gradient elution was carried out sequentially with a mixture of CH2Cl2, CH2Cl2, CH3OH, and NH4OH for 20 min. The volume ratio of CH2Cl2, CH3OH, and NH4OH in the mixture was 75:22:

3.

3. The preparation method according to claim 2, characterized in that, In step (1), the molar ratio of lipids, cholesterol, distearate phosphatidylcholine and DMG-PEG 2000 is 50:38.5:10:1.

5.

4. The production method according to claim 2, wherein In step (1), the conditions for generating the thin film are: rotary evaporation at 37°C for 30 min.

5. The production method according to claim 2, wherein In step (1), the concentration of ammonium sulfate is 250 mM and the hydration time is 1 h.

6. The production method according to claim 2, wherein The molar ratio of 1,3-propanediamine to 1,2-epoxyhexane is 1:1; the high-temperature stirring conditions are: stirring at 90°C for 2.5 h.

7. The production method according to claim 2, wherein In step (2), the molar ratio of the liposome to the siRNA is (15-70):

1.

8. The use of the liposome nanocarrier as described in claim 1 in the preparation of a medicament for treating allergic rhinitis.

9. A medicament for targeted treatment of allergic rhinitis, characterized in that, This includes the liposome nanocarriers as described in claim 1, as well as pharmaceutically acceptable carriers.

Images